In the past week, LEGN stock has gone up by 32.61%, with a monthly gain of 18.63% and a quarterly surge of 1.37%. The volatility ratio for the week is 4.74%, and the volatility levels for the last 30 days are 4.61% for Legend Biotech Corp ADR The simple moving average for the past 20 days is 25.28% for LEGN’s stock, with a -2.77% simple moving average for the past 200 days.
Is It Worth Investing in Legend Biotech Corp ADR (NASDAQ: LEGN) Right Now?
The 36-month beta value for LEGN is also noteworthy at 0.14. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 10 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for LEGN is 181.38M, and at present, short sellers hold a 4.18% of that float. The average trading volume of LEGN on June 10, 2025 was 1.62M shares.
LEGN) stock’s latest price update
Legend Biotech Corp ADR (NASDAQ: LEGN) has seen a rise in its stock price by 8.40 in relation to its previous close of 34.78. However, the company has experienced a 32.61% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-10 that NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation (“Legend Biotech Corporation”) (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Analysts’ Opinion of LEGN
Many brokerage firms have already submitted their reports for LEGN stocks, with Redburn Atlantic repeating the rating for LEGN by listing it as a “Buy.” The predicted price for LEGN in the upcoming period, according to Redburn Atlantic is $86 based on the research report published on October 08, 2024 of the previous year 2024.
Truist, on the other hand, stated in their research note that they expect to see LEGN reach a price target of $88. The rating they have provided for LEGN stocks is “Buy” according to the report published on June 17th, 2024.
H.C. Wainwright gave a rating of “Buy” to LEGN, setting the target price at $73 in the report published on May 24th of the previous year.
LEGN Trading at 18.77% from the 50-Day Moving Average
After a stumble in the market that brought LEGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.06% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at LEGN starting from Casey Patrick John, who proposed sale 1,000 shares at the price of $32.32 back on Jun 06 ’25. After this action, Casey Patrick John now owns shares of Legend Biotech Corp ADR, valued at $32,320 using the latest closing price.
Huang Ying, the Officer of Legend Biotech Corp ADR, proposed sale 6,548 shares at $34.55 during a trade that took place back on May 01 ’25, which means that Huang Ying is holding shares at $226,233 based on the most recent closing price.
Stock Fundamentals for LEGN
Current profitability levels for the company are sitting at:
- -0.32 for the present operating margin
- 0.66 for the gross margin
The net margin for Legend Biotech Corp ADR stands at -0.3. The total capital return value is set at -0.17. Equity return is now at value -20.00, with -12.87 for asset returns.
Based on Legend Biotech Corp ADR (LEGN), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -11.16.
Currently, EBITDA for the company is -113.16 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 4.64. The receivables turnover for the company is 4.37for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.20.
Conclusion
In summary, Legend Biotech Corp ADR (LEGN) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
